New User Account Set Up

If you do not have an account with the Digest, please click on "Submit to the Digest." By logging in with your UCLA Login ID (formerly known as BOL Login), a new account will automatically be generated. If you experience any difficulties, please send an email to our help desk:


If you have any questions or concerns, please email our help desk/support team: We are more than happy to address any questions or concerns regarding the Weekly Message Digest system you may have.

How do I subscribe?

If you have a mednet email account (, you should already be subscribed.

If you do not have a mednet email account or you are not receiving the Digest, please send an email to and we will add you to our list.

Is your patient having trouble taking their HIV medication consistently every day?

This study is testing if combination injectable, long-acting anti-HIV drugs can be used successfully in people living with HIV who have a detectable viral load because they have difficulty taking oral HIV medications every day. In the first few months, participants will receive additional financial incentives for staying on oral medications to lower the viral load and ultimately getting their viral load undetectable.  For people whose viral load is undetectable at the end of this initial period, they will be randomized (like a flip of a coin) to stay on the daily oral treatment or start an injectable treatment regimen.

The study will last between 6 months and 3 ½ years depending on successful completion of each milestone in the study.

Basic eligibility criteria:

  • Age 18 and older.
  • Prescribed ART for at least 6 months.
  • Have trouble taking HIV medication as prescribed.
  • Have HIV viral load greater than 200 copies and/or show evidence of non- adherence.
  • Not pregnant, breastfeeding or planning to become pregnant.


Posting Information
This posting expired on September 16, 2022.
Posting Attachment: Download Attachment

Share this posting on social media!